AbbVie entered a definitive agreement to acquire Cerevel Therapeutics and its neuroscience pipeline of multiple clinical-stage and preclinical candidates with potential across schizophrenia, Parkinson’s disease (PD), and mood disorders, approximately $8.7 billion. The acquisition complements AbbVie’s neuroscience portfolio, adding a wide range of potentially best-in-class assets that may transform standards of care across psychiatric and neurological disorders where significant unmet...